Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, announced preliminary results from a clinical trial evaluating its Ovarian Tumor Triage Test. The study met its primary endpoints, demonstrating that the test successfully stratifies women with pelvic masses into high- and low-risk categories to determine whether the patient should be referred to a specialist prior to surgery.